Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Aug 25 · below the Ichimoku cloud · RSI 44 · MACD below its signal
None of the 29 investors followed here reported a position in GLSI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GLSI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 28, 2026 | Patel SnehalChief Executive Officer | Purchase at price 13.10 - 13.59 per share. | 2.2K | $29.55K |
| Jul 26, 2026 | Patel SnehalOfficer, Director and Beneficial Owner | Purchase at price 13.62 per share. | 1.5K | $20.43K |
| Jul 23, 2026 | Patel SnehalChief Executive Officer | Purchase at price 12.88 - 13.14 per share. | 3.6K | $47.02K |
| Jan 12, 2026 | Patel SnehalChief Executive Officer | Purchase at price 29.83 per share. | 1.8K | $53.69K |
| Jan 11, 2026 | Patel SnehalChief Executive Officer | Purchase at price 27.54 per share. | 2.9K | $79.87K |
| Dec 30, 2025 | Patel SnehalChief Executive Officer | Purchase at price 21.36 per share. | 4.3K | $91.85K |
| Dec 29, 2025 | Patel SnehalChief Executive Officer | Purchase at price 21.73 per share. | 2.9K | $63.02K |
| Dec 17, 2025 | Patel SnehalChief Executive Officer | Purchase at price 12.62 per share. | 4.1K | $51.74K |
| Nov 24, 2025 | Patel SnehalChief Executive Officer | Purchase at price 8.37 per share. | 4.6K | $38.50K |
| Nov 6, 2025 | Patel SnehalChief Executive Officer | Purchase at price 8.43 per share. | 10.6K | $89.36K |
| Oct 30, 2025 | Patel SnehalChief Executive Officer | Purchase at price 9.26 per share. | 2.3K | $21.30K |
| Apr 24, 2025 | Patel SnehalChief Executive Officer | Purchase at price 9.88 per share. | 3.6K | $35.57K |
| Apr 16, 2025 | Patel SnehalChief Executive Officer | Purchase at price 8.98 per share. | 5.4K | $48.49K |
| Apr 6, 2025 | Patel SnehalChief Executive Officer | Purchase at price 9.10 per share. | 3.6K | $32.76K |
| Apr 3, 2025 | Patel SnehalChief Executive Officer | Purchase at price 8.73 per share. | 5.5K | $48.02K |
| Jan 9, 2025 | Patel SnehalChief Executive Officer | Purchase at price 12.51 per share. | 2.5K | $31.27K |
| Jan 6, 2025 | Patel SnehalChief Executive Officer | Purchase at price 13.31 - 13.75 per share. | 2.9K | $39.39K |
| Jan 2, 2025 | Patel SnehalChief Executive Officer | Purchase at price 12.95 per share. | 3.4K | $44.03K |
| Jan 1, 2025 | Patel SnehalChief Executive Officer | Purchase at price 11.97 per share. | 2K | $23.94K |
| Dec 30, 2024 | Patel SnehalChief Executive Officer | Purchase at price 11.36 per share. | 2.4K | $27.26K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 43.1 | -7.8 | -13.3 | -1.7 | 10.8 | -10.4 | -42.5 | 10.7 | 20.7 | -14.1 | −26.2% | ||
| 2025 | 15.2 | -5.6 | -21.9 | 5.9 | -2.5 | -7.9 | 20.6 | 4.9 | -13.3 | -7.4 | -5.2 | 140.7 | +87.1% |
| 2024 | -17.9 | 40.7 | 64.0 | -37.7 | 19.4 | 16.4 | -6.6 | -13.0 | 2.5 | -6.4 | 5.9 | -21.2 | +6.7% |
| 2023 | 30.5 | -21.3 | -11.7 | -22.3 | 1.7 | -11.4 | -4.6 | -0.3 | -3.6 | -5.4 | 40.0 | -10.1 | −30.8% |
| 2022 | -24.1 | 5.5 | 0.7 | -39.6 | -34.7 | 9.4 | -4.5 | 17.2 | -4.0 | -1.0 | 54.8 | 9.0 | −37.5% |
| 2021 | 2.8 | -16.5 | 8.8 | 10.3 | -1.4 | 21.2 | -12.2 | 1.4 | -2.4 | -9.5 | -11.1 | -22.6 | −33.3% |
| 2020 | -23.7 | 51.0 | 588.1 | +692.8% |
Buy / hold / sell counts
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.